Navigation Links
Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD)
Date:10/26/2011

CAMBRIDGE, Mass., Oct. 26, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) announced today that it will report its financial results for the third quarter of 2011 on Wednesday, November 2, 2011 after U.S. financial markets close.

Idenix management will host a conference call at 4:30 p.m. ET on Wednesday, November 2, 2011 to discuss the company's financial results for the third quarter of 2011 and provide an update on the company's development programs.

To access the call please dial (877) 640-9809 U.S./Canada or (914) 495-8528 International and enter passcode 22292830. There will also be a slide presentation available to accompany the conference call, which can be accessed on our website in the Idenix Investor Center at www.idenix.com.  To listen to a live webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 10 minutes before the call to ensure a timely connection. A replay of the conference call and webcast will be available until November 16, 2011. To access the replay, please dial (855) 859-2056 U.S./Canada or (404) 537-3406 International and enter the passcode 22292830.

American Association for the Study of Liver Diseases Meeting (AASLD)
Idenix will present two posters at AASLD in San Francisco, California:

  • McCarville, et al, "Patterns of NS5B mutations in a 3-day clinical trial of HCV non-nucleoside polymerase inhibitor IDX375" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT
  • McCarville, et al, "In vivo resistance profile of IDX320 after 3 days of dosing in genotype 1 HCV-infected patients" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT

About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033  (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
3. Idenix Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Idenix Pharmaceuticals Prices Public Offering of Common Stock
6. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
7. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
10. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... July 13, 2017  Centurion Medical Products, a leader in medical ... ® fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are ... help alleviate patient pain while preventing unneeded emergency department admission due ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
(Date:7/11/2017)... July 11, 2017  Sysmex America, Inc., a ... testing equipment as well as middleware information systems ... to make quality assurance easier and more risk ... well known for the innovation that it delivers ... elevates quality assurance processes to a new level ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... ... further expand its existing adherence automation lines. The ATP® Mini and InspectRx® ... technology of TCG’s standard products, but at a size and price point that ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, a ... major international travel insurance products online, under their own brand. The online marketplace ...
(Date:7/20/2017)... ... 2017 , ... A local summer theatre camp is celebrating ... support fine arts programs in Chester County’s Elementary Schools. In late June, students ... , More than 850 people attended the two performances, an increase from ...
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... Med Tech ... the Minnesota based Health IT business unit of Constellation Inc., a move that will ... established base of operations in St. Louis, the acquisition is expected to help ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th ... weight loss surgery patients who had received a body contouring procedure reported experiencing a ... clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that this ...
Breaking Medicine News(10 mins):